Trial Profile
First Human Dose Trial of NNC0114-0000-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-interleukin-21 monoclonal antibody (Primary) ; Anti-interleukin-21 monoclonal antibody (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
- 02 Feb 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 28 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.